On September 27, 2019 (108th year of the ROC), the Food and Drug Administration of the Ministry of Health and Welfare (TFDA), Republic of China, issued an official Class II drug recall notice regarding Apo-Ranitidine 150mg F.C. Tablets distributed by Horng Wey Pharmaceutical Co., Ltd., following manufacturer notifications that raw active pharmaceutical ingredients (APIs) were contaminated with potential carcinogenic impurities.

Product Recall Specifications

  • Product Name: Apo-Ranitidine 150mg F.C. Tablets
  • Therapeutic Indications: Duodenal ulcers, benign gastric ulcers, reflux esophagitis, marginal peptic ulcers, hypersecretory gastric conditions (e.g., Zollinger-Ellison syndrome)
  • Active Ingredient: Ranitidine Hydrochloride (Ranitidine HCl)
  • License Registration Number: DOH-PI-No. 020323
  • Affected Batch Numbers: NA3627, NE8861, NP5652, NV9126, PY9164
  • Marketing Authorization Holder: Horng Wey Pharmaceutical Co., Ltd.
  • Reference Photograph:

Regulatory Recall Information

  • Recall Classification: Class II
  • Official Dispatch Notice: FDA Drug Division No. 1081410043 (September 27, 2019)
  • Publication Date: September 28, 2019
  • Recall Rationale: Precautionary voluntary market withdrawal initiated after tests indicated that API lots utilized in the formulated tablets carried risk of N-Nitrosodimethylamine (NDMA) impurities exceeding safety limits.

Further Reading & References

  1. TFDA Pharmaceutical Recall Classification and Standard Operating Procedures
✦ Independent Journalism · Reader Support ✦

Support Independent Perspectives & In-Depth Insights

Every thoughtful analysis and candid critique comes from our dedication to truth and quality. We choose not to follow sensational algorithms or clickbait headlines.

Sustaining independent research requires reader support. Make a one-time or monthly contribution, securely processed by Google.

Payments secured by Google · Manage or cancel anytime in your Google Account